

JUN 02 2006

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

TO: Amendment - United States Patent and Trademark Office

Fax No. 571-273-8300

Phone No.

FROM: Cindy Lukas

Fax No. 513-622-3300

Phone No. 513-622-1692

Application No.: 10/770,138

Inventor(s): Rennie et al.

Filed: February 2, 2004

Docket No.: 9510

Confirmation No.: 9660

FACSIMILE TRANSMITTAL SHEET ANDCERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on June 2, 2006, to the above-identified facsimile number.

Cindy Lukas (Signature)

Listed below are the item(s) being submitted with this Certificate of Transmission:**

- 1) Supplemental Information Disclosure Statement (2pg.)
- 2) PTO-SB08 (1 pg.)
- 3) Reference (2 pgs.)
- 4)
- 5)

Number of Pages Including this Page: 5

Comments:

**Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

JUN 02 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/770,138
Inventor(s) : Rennie et al.
Filed : February 2, 2004
Art Unit : 1617
Examiner :
Docket No. : 9510
Confirmation No. : 9660
Customer No. : 27752
Title : Methods of Prevention and Treating SARS Using Low pH
Respiratory Tract Compositions

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of document(s) which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited document(s) be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the document(s) listed on attached form PTO/SB08 is (are), or is (are) considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company.

Appl. No. 10/770,138
Docket No. 9510
Customer No. 27752
Paper dated June 2, 2006


2

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Kristin Kohler

Typed or printed name
Registration No. 41,907
(513) 622-3371

Date: June 2, 2006
Customer No. 27752
9510IDS.doc

JUN 02 2006

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <p style="text-align: center;">STATEMENT BY APPLICANT (use as many sheets as necessary)</p>	<p style="text-align: center;">COMPLETE IF KNOWN</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/770,138</td> </tr> <tr> <td>Confirmation Number</td> <td>9660</td> </tr> <tr> <td>Filing Date</td> <td>February 2, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Paul John Rennie</td> </tr> <tr> <td>Group Art Unit</td> <td>1617</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>9510</td> </tr> </table>	Application Number	10/770,138	Confirmation Number	9660	Filing Date	February 2, 2004	First Named Inventor	Paul John Rennie	Group Art Unit	1617	Examiner Name		Attorney Docket Number	9510
Application Number	10/770,138														
Confirmation Number	9660														
Filing Date	February 2, 2004														
First Named Inventor	Paul John Rennie														
Group Art Unit	1617														
Examiner Name															
Attorney Docket Number	9510														

SHEET 1 of 1

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US - 6,294,186 B1	09/25/2001	Beerse et al.	
EXAMINER				DATE CONSIDERED	

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	2	ZHAORI GETU: "Antiviral Treatment Of SARS: Can We Draw Any Conclusions?", Canadian Medical Association Journal, November 25, 2003, vol. 169, no. 11, pgs. 1165-1166.. XP-002378394	
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S.

Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08